MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
In recent years, major advances have been made in cancer immunotherapy. This has led to significant improvement in prognosis of cancer patients, especially in the hematological setting. Nonetheless, translation of these successes to solid tumors was found difficult. One major mechanism through which...
Main Authors: | Annelisa M. Cornel, Iris L. Mimpen, Stefan Nierkens |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/7/1760 |
Similar Items
-
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
by: Elena Shklovskaya, et al.
Published: (2021-06-01) -
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
by: Karthik Dhatchinamoorthy, et al.
Published: (2021-03-01) -
MHC Class I Stability is Modulated by Cell Surface Sialylation in Human Dendritic Cells
by: Zélia Silva, et al.
Published: (2020-03-01) -
In vivo Downregulation of MHC Class I Molecules by HCMV Occurs During All Phases of Viral Replication but Is Not Always Complete
by: Florin Gabor, et al.
Published: (2020-06-01) -
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
by: Shixiang Wang, et al.
Published: (2019-11-01)